Study Summary
This trial will study whether onvansertib is safe and effective at treating small cell lung cancer in patients who can't tolerate or haven't responded to chemotherapy.
- Small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to 3.5 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Single Treatment Arm
1 of 1
Experimental Treatment
37 Total Participants · 1 Treatment Group
Primary Treatment: Onvansertib · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are we currently looking for more participants for this clinical trial?
"The trial, which was originally posted on 7/19/2022 and updated last on 7/29/2022, is presently recruiting patients as reported by clinicaltrials.gov" - Anonymous Online Contributor
How many volunteers are currently enrolled in this experiment?
"Indeed, the trial is presently recruiting patients as indicated by information on clinicaltrials.gov. The original posting was on 7/19/2022 and there have been 37 edits as of 7/29/2022. Currently, 1 sites are looking for participants." - Anonymous Online Contributor
What are the potential Onvansertib side effects that patients should be aware of?
"Onvansertib's safety is supported by some data, but since this is only a Phase 2 trial, there is no evidence yet of its efficacy. Therefore, it received a score of 2." - Anonymous Online Contributor